stockportfolio.pro
Stocks / NBIX vs ZBH
NBIX vs ZBH
Neurocrine Biosciences, Inc. and Zimmer Biomet Holdings, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Neurocrine Biosciences, Inc. (NBIX) | Zimmer Biomet Holdings, Inc. (ZBH) | |
|---|---|---|
| Market cap | $16.3B | $17.3B |
| Revenue (latest FY) | $2.86B | $8.23B |
| Net income (latest FY) | $478.60M | $705.10M |
| Revenue growth (5y CAGR) | 22.3% | 6.1% |
| Net margin | 16.7% | 8.6% |
| Return on equity | 14.7% | 5.6% |
| P/E ratio | 25.0 | 23.2 |
| Dividend yield | — | 1.1% |
| Profitable years (of last 10) | 8 | 8 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open NBIX — free Open ZBH — freeFrequently asked questions
Which is bigger, NBIX or ZBH?
Zimmer Biomet Holdings, Inc. is larger by market capitalization — $17.3B versus $16.3B.
Which grows faster, NBIX or ZBH?
Over the last five fiscal years, Neurocrine Biosciences, Inc. grew revenue faster — 22.3%/yr versus 6.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.